Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study.
Suchita PakkalaKristin HigginsZhengjia ChenGabriel SicaConor SteuerChao ZhangGuojing ZhangShuhua WangMohammad S HossainBassel NazhaTyler BeardsleeFadlo R KhuriWalter CurranSagar LonialEdmund K WallerSuresh RamalingamTaofeek Kunle OwonikokoPublished in: Journal for immunotherapy of cancer (2021)
The D/T combination with and without SBRT was safe but did not show sufficient efficacy signal in relapsed SCLC. Changes in peripheral blood lymphocyte and TILs were consistent with an immunologic response.Trial registration number NCT02701400.
Keyphrases
- peripheral blood
- phase ii study
- radiation therapy
- locally advanced
- small cell lung cancer
- acute lymphoblastic leukemia
- acute myeloid leukemia
- hodgkin lymphoma
- multiple myeloma
- diffuse large b cell lymphoma
- open label
- phase iii
- phase ii
- study protocol
- clinical trial
- rectal cancer
- placebo controlled
- brain metastases
- squamous cell carcinoma
- randomized controlled trial